Archive: 13/02/2019
New assay selects patients with lung cancer for treatment with immune checkpoint inhibitors
Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer (NSCLC). Assessing the level of programmed death ligand 1 (PD-L1) expressed by ...
Feb 13, 2019